One million doses of Covishield vaccine from India by Saturday

One million doses of the Covishield vaccine purchased by Nepal from the government of India last February will be arriving by this Saturday.

सम्बन्धित सामग्री

India's Serum Institute applies for full approval of Covishield vaccine

Serum Institute Of India has applied to the country's drug regulator and the health ministry for full approval of its COVID-19 vaccine Covishield, the company's chief executive said on Friday.

972,000 doses of Covishield vaccine arriving in Nepal today

KATHMANDU, Dec 1: As many as 972,000 doses of Covishield vaccine from the Serum Institute of India are set to arrive in Nepal today.

725,000 doses of Covishield vaccine arrive

Nepal has received additional 725,000 doses of Covishield, the AstraZeneca type vaccine manufactured by the Serum institute of India, from the COVAX facility. It is a part of the 6 million doses of the vaccine committed to be provided through the COVAX facility supported by the United Nations. “We have received 725,550 doses of Covishield from COVAX facility,” said Upendra Dhungana, chief of Logistic Management Section under the Department of Health Services. The second consignment of the vaccine with 972,000 doses will arrive soon, added Dhungana.

Infographics: Nepal’s COVID-19 vaccination status

KATHMANDU, Aug 15: Nepal had launched the vaccination drive against the novel coronavirus disease (COVID-19) on January 27, last year.  Since then, a total of 1,868,425 people have received the first shot of the Covishield vaccine (manufactured by Serum Institute of India), Japanese-made COVID-19 AstraZeneca vaccine and Swedish AstraZeneca vaccine. Similarly, 774,533 people have received the second jab of the same vaccine. The government has been administering the second jab of AstraZeneca vaccine to those who had received the first dose before April, earlier this year.  According to the data released by the Ministry of Health and Population (MoHP),  2,805,893 people have so far been inoculated with the first dose of Chinese-made Verocell vaccine while 1,255,411 have received both the doses.  Government data revealed that 1,273,634 shots of the US-manufactured Johnson and Johnson (J&J) vaccine  have been administered throughout the country. Nepal had received 1.6 million of single-shot J&J vaccines from the United States under grant assistance.  See the province-wise data:

AstraZeneca vaccine for people above 65 as second dose of Covishield

KATHMANDU, August 9: The Ministry of Health and Population has launched the AstraZeneca vaccination drive targeting the senior citizens above 65 years of age who have received the first dose of Covishield vaccine.  The two-day vaccination campaign kicked off today. According to Ministry's joint-spokesperson Dr Samir Kumar Adhikari, the campaign was launched following the arrival of AstraZeneca vaccines from Bhutan and Japan.  Covishield and AstraZeneca vaccine are developed by the same company and based on the same formula, with different brand names.  It makes no difference for those already getting the first jab of Covishield to receive the AstraZeneca as the second dose. Senior citizens receiving the first dose of Covishield are to get the second dose after around four and half months of receiving the first dose.  Some 1.4 million people above 65 years of age were given the first dose of Covishield from March 7 to 24.  The second dose was delayed as vaccine purchased from India was not supplied.  The vaccine is available from 149 vaccination centres in the capital.

Govt to bring 18.3 million doses of COVID-19 vaccine by mid October

KATHMANDU, July 31: The government is to bring 18.3 million doses of anti-COVID vaccine by coming mid October. Releasing a press statement on Friday, Spokesperson at Ministry of Health and Science, Dr Krishna Prasad Poudel, informed that a total of 18.3 million dozes of anti-COVID vaccines were being brought from China, Japan and India combined. Agreement on vaccine purchase from China was already forwarded. Similarly, Japan government is providing vaccine under Covax scheme. The additional one million doses of Covishield from India is also coming.

AstraZeneca vaccine to be administered as alternative to Covishield

KATHMANDU, June 7: The government is  preparing to administer the AstraZeneca COVID-19 vaccine as an alternative to the booster dose the Covishield vaccine. The government ‘s decision comes after the Serum Institute of India, the manufacturing company of Covishield vaccine and the COVAX Facility expressed inability to supply additional quantities of Covishield vaccines to Nepal for the time being.  The Ministry of Health and Population (MOHP) is planning to administer the AstraZeneca vaccine for those waiting for the booster shot of Covishield as both vaccines are similar in nature and composition. Director of Family Welfare Division, Department of Health Services, Dr Taranath Pokhrel said that  AstraZeneca will be provided  to those receiving the first jab of Covishield as both vaccines were developed by the same company being based on the same formula and methodology and it would make no difference in giving the AstraZeneca as an alternative to the Covishield. The vaccination schedule is yet to be fixed. The booster or second dose is to be taken after 12-16 weeks of getting the first shot.   \Around 1.4 million people above 65 years of age were provided the first shot of Covishield from 7th March to  23rd March.  They are waiting for the final shot as the Serum Institute of India expressed its inability to supply one million doses of vaccines that Nepal had procured from the company for the time being in view of the increasing infections rate in India.  So far in Nepal, the number of the population receiving the first shot of COVID-19 jab stands at 2.13 million while 691,184 have received the full course. The government is administering the China –manufactured Vero Cell to the people from 60-64 age group from tomorrow, Tuesday.

South Asia’s vaccine geopolitics

Nepal took delivery of one million doses of Covishield vaccine ordered from the Serum Institute of India, on Sunday. Photo: AMIT MACHAMASI midst the pandemic, Covid-19 vaccines have become a means for countries to exert influence over others. This has seen global powers flex their manufacturing prowess to reap geopolitical gains. As a landlocked country […]